Atea blueprints Phase 3 for hepatitis C combo after mid-stage winnews2024-12-04T12:00:56+00:00December 4th, 2024|Endpoints News|
Lilly wins head-to-head weight loss trial against Novo Nordisknews2024-12-04T11:45:47+00:00December 4th, 2024|Endpoints News|
GSK terminates Phase 2 trial of HBV therapeutic vaccinenews2024-12-03T20:23:03+00:00December 3rd, 2024|Endpoints News|
Ipsen secures rights to T cell engager in $610M pact with Biomunexnews2024-12-03T16:27:53+00:00December 3rd, 2024|Endpoints News|
Cartesian tees up Phase 3 mRNA CAR-T study in myasthenia gravisnews2024-12-03T15:51:57+00:00December 3rd, 2024|Endpoints News|
Roivant says long-shot drug for a rare lung disease failed its Phase 2 studynews2024-12-03T14:36:06+00:00December 3rd, 2024|Endpoints News|
Revolution sells $600M in shares on back of RAS inhibitor portfolio updatesnews2024-12-03T11:59:18+00:00December 3rd, 2024|Endpoints News|
Janux soars on 50% response rate in later-line prostate cancer trialnews2024-12-03T11:13:19+00:00December 3rd, 2024|Endpoints News|
Olema, Novartis ink another agreement, this time for a late-stage breast cancer trialnews2024-12-02T15:58:33+00:00December 2nd, 2024|Endpoints News|
Novocure says electric field therapy extends life for pancreatic cancer patients by two monthsnews2024-12-02T15:48:56+00:00December 2nd, 2024|Endpoints News|
